Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort
Active, not recruiting · NCT06081361 · Registry updated 2025-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Innovating Shorter, All- Oral, Precised, Individualized Treatment Regimen for Rifampicin Resistant Tuberculosis：Contezolid, Delamanid and Bedaquiline Cohort | Actinomycetales infectious disease, Bacterial Infections and Mycoses, Infections, bacterial infectious disease, gram-positive bacterial infections, lung disorder, mycobacterial infectious disease, pulmonary tuberculosis, respiratory system disorder, respiratory tract infectious disorder, rifampicin-resistant tuberculosis, tuberculosis | Active, not recruiting | Phase 3 | 2025-04-01 | NCT06081361 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Beijing Chest Hospital | 17 |
| National Center for Infectious Diseases | 2 |
39 results · Page 1 of 2
Research sites
Swipe the table sideways for more columns.